



11W 2821

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Reply, Refer to the Application of: Qiwang Xu et al.

Serial No.: 10/551,081

Filed: March 29, 2007

Title: USE OF N-ACETYL-D-GLUCOSAMINE
IN TREATMENT OF LOCAL LESIONS
OR SYSTEMATIC SYMPTOMS
RELATED TO AUTOIMMUNE
REACTIONS

Seyfarth Shaw Matter: 33888-400200

Date: August 28, 2007

)
) Group Art Unit: 2821
)
) Confirmation No. 1679
)
) **Customer No. 27717**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Applicants' assignee's undersigned attorneys, are aware of the references listed on the attached Form PTO/SB/08A and 8B, copies of which are enclosed, and which are relevant to said application.

It is believed that no fee is required. However, if there is a fee, you are authorized to charge same to Deposit Account No. 19-1351.

Respectfully submitted,

Seyfarth Shaw LLP
Attorneys for Assignee
131 S. Dearborn Street - Suite 2400
Chicago, Illinois 60603-5577
312-460-5000

By: 
Harold V. Stotland (Reg. No. 24,492)

+

+

+

+

+

Complete if Known

Application Number	10/551,081
Filing Date	March 29, 2007
First Named Inventor	Qiwang Xu
Group Art Unit	2821
Examiner Name	
Attorney Docket Number	33888-400200

Attorney Docket Number	33888-400200
------------------------	--------------

Sheet	2	of	3
-------	---	----	---

[illegible][illegible]

Date Considered

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known	
		Application Number	10/551,081
		Filing Date	March 29, 2007
		First Named Inventor	Qiwang Xu
		Art Unit	2821
		Examiner Name	
Sheet 3	of 3	Attorney Docket Number	33888-400200

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Manna R., et al. "psoriasis: an autoimmune disease" Minerva Medica, 1992, Italy, vol. 83, no. 7-8, 1992, pages 403-414	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.